Saritha A

Oral Lichen Planus (OLP) is a chronic inflammatory disease that affects the mucous and cutaneous tissue inside our mouth. It is a T cell mediated autoimmune disease. The two major types of OLP are Reticular OLP and Erosive OLP. They appear as white, lacy, patches, red coloured, swollen tissues or open sores. Its cause is unknown. The oral lichen planus do not pass from one person to another. This disease may be sometimes responsible for developing mouth cancer. Proper monitoring is needed for the patients who are having oral lichen planus. Personal oral hygiene is believed to reduce the symptoms of OLP. The topical or systemic corticosteroids modulate the patient’s immune response. The natural treatments by using aloe vera, yogurt, turmeric, almonds, baking soda and lemon are very much effective in treating OLP. The commonly used homeopathic medicines used for the treatment of OLP are plantaga, mercsol and borax. The non pharmacological approaches used for treating OLP include PUVA therapy, laser therapy, cryotherapy and CO2 laser. Nowadays modalities like retinoids, dapsone, hydroxychloroquine, calcineurin inhibitors and mycophenolatemofetil are used for treatment.

The eye presents unique opportunities and challenges for the delivery of pharmaceutical dosage forms. Ocular inserts of Moxifloxacin HCl were prepared with the objective of reducing frequency of administration, controlled release and greater therapeutic effect. Moxifloxacin HCl a broad spectrum fourth generation fluroquinolone used in the treatment of conjunctivitis, keratitis, kerato-conjunctivitis etc. In the present wok reservoir type of ocular inserts formulated by sandwiching poly vinyl alcohol containing Moxifloxacin HCl in between two rate controlling membranes of ethyl cellulose and PVP-K30. The reservoir types of ocular inserts containing Moxifloxacin HCl were formulated by film casting technique using PVA as drug reservoir polymer and EC: PVP-K30 as a rate controlling material. In vitro drug release revealed that the optimized (FM6) formulation showed a controlled release. In vivo studies showed a release of 97.67% over a period of 5 days with high correlation coefficient  of  In vitro-In vivo release studies. In the present study the ocular inserts of Moxifloxacin HCl (FM6) provided desired drug release for 5 days and remained stable.